Marco Meglio

Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.

The head of the MS Center at the University of Basel discussed an analysis presented at CMSC’s Annual Meeting, focusing on the effects of BTK inhibitor evobrutinib on neurofilament light levels.

After 30 days of the PennPALS system, 70.8% of the remaining 24 patients were adherent to treatment or were using their PAP machine for at least 4 hours/night on average over the last 7 days.

Among those observed in the trial, Black pregnant women had a mean number of 4.20 sessions of cognitive behavioral therapy compared with 5.54 for White pregnant women.

In subanalyses of ISI responders with chronic insomnia, those in the lemborexant 10-mg group demonstrated significantly greater changes from baseline in sleep onset latency compared with placebo.

The IDSIQ showed score changes that correlated with clinically meaningful improvement on various responder definition estimates following triangulation.

A combination of less sleep and high cardiovascular disease risk tended to be associated with greater decline in executive function.

In comparison to White participants, non-Hispanic Black individuals reported shorter sleep duration and more sleep disturbances while the opposite was observed for Hispanic individuals.

Overall, 49% of respondents with idiopathic hypersomnia were reportedly dissatisfied with the management of their condition.

Although the sample size was relatively small, the findings provide insight into predictors of adherence to CPAP, which has been known to limit the effectiveness of the therapy.

Between those treated with CPAP and those who withdrew treatment, the difference in N3 sleep represented 15.7% of variance beyond a base model that included age and sex alone.

Avoidance of cardiovascular issues and effects, as well as improved effort to gain control of narcolepsy symptoms, were among the reasons for switching to lower sodium oxybate.

After a previous analysis showed that natalizumab dosing every 6 weeks can decrease the risk of progressive multifocal leukoencephalopathy, new data showed no differences in patient-reported outcomes vs treatment every 4 weeks.

Clinician-perceived cognitive deficits of patients with multiple sclerosis were significantly predicted by multiple factors, including cognitive scores, depression, and physical disability, but notably not fatigue.

Individuals with progressive MS demonstrated stable scores on Expanded Disability Status Scale, with no 12-week confirmed disability progression detected.

A large number of patients with MS were clustered in an area that may have had high exposure levels of aluminum, which the study investigators noted warrants future research.

At the end of the open-label extension period, 77.5% of patients reported treatment-emergent adverse events and 27.7% had a treatment-related TEAE.

Although there were no differences between herpes simplex virus types 1 and 2, patients with MS did show increased levels of EBV capsid antigen and EBNA compared with controls.

Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.

The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.

Data from the RAINBOWFISH study and a large-scale extension, FIREFISH, were the basis for risdiplam’s expanded indication, which now includes babies with SMA under 2 months old.

More than 60% of adolescents felt that it was more important to measure decreases in the frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days.

Emily Harrington, MD, PhD, physician-scientist at The Ohio State University Wexner Medical Center, provided thoughts on the importance of World MS Day and the issues that plague the MS community.

Investigators identified a duration-response pattern that was also present within the strata of high vs low-medium intensity statin therapy in a cohort of more than 16,000 individuals.

Composite SOT scores—lower in patients with migraine vs controls—were moderately correlated with fear of falling, dizziness disability, kinesiophobia, and migraine frequency.

The proportion of patients who achieved an at least 50% reduction in monthly migraine days was significantly higher among those on either erenumab dose compared with placebo.

Among participants with a high dementia polygenic risk score, the 12-year cumulative incidence of dementia was 4.3% for those with hypertension compared with 2.8% for those without.

Falls, a common occurrence for patients with spinocerebellar ataxia, were significantly reduced following treatment with troriluzole after 48 weeks.

Patients with relapsing multiple sclerosis who had progression independent of relapse activity were subject to global brain tissue loss similar to that of patients experiencing solely relapse activity.

Although neutropenic fever was common among patients, there was no significant difference between disease-modifying therapies, including those with long-lasting effects.